A vaccine against serogroup B Neisseria meningitidis: Dealing with uncertainty

The Lancet Infectious Diseases

Volumn 14, Issue 5, 2014, Pages 426-434

  Andrews, Sophie M ^a   Pollard, Andrew J ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHILD; COST-BENEFIT ANALYSIS; EUROPEAN UNION; HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; UNCERTAINTY;

EID: 84899415248     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70341-4     Document Type: Review

References (81)

1. Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012, 11:774-783.
2. Christensen H, May M, Bowen L, Hickman M, Trotter CL Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010, 10:853-861.
3. Invasive meningococcal infections laboratory reports, England and Wales by capsular group & epidemiological year, 1998/99-2011/12, 14/09/2012 Health Protection Agency, (accessed Aug 4, 2013). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136087064.
4. Active Bacterial Core Surveillance (ABCs) report-emerging infections program network: Neisseria meningitidis, 2012-provisional Centers for Disease Control and Prevention, (accessed Dec 11, 2013). http://www.cdc.gov/abcs/reports-findings/survreports/mening12.pdf.
5. Australian meningococcal surveillance programme annual reports, 1998-2012 Australian Government Department of Health, (accessed Jan 31, 2014). http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-menganrep.htm.
6. Meningococcal disease annual report 2011, Health Protection Surveillance Centre, Health Protection Surveillance Centre, Dublin.
7. Invasive meningococcal C infections laboratory reports, England and Wales by age group & epidemiological year, 1998/99-2011/12, 14/09/2012 Health Protection Agency, (accessed April 14, 2013). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136089480.
8. Goldschneider I, Gotschlich EC, Artenstein MS Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
9. Finne J, Leinonen M, Mäkelä PH Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983, 322:355-357.
10. Häyrinen J, Jennings H, Raff HV, et al. Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis 1995, 171:1481-1490.
11. Beveridge TJ Structures of gram-negative cell walls and their derived membrane vesicles. J Bacteriol 1999, 181:4725-4733.
12. Martin DR, Ruijne N, McCallum L, O'Hallahan J, Oster P The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol 2006, 13:486-491.
13. Oster P, Lennon D, O'Hallahan J, Mulholland K, Reid S, Martin D MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005, 23:2191-2196.
14. van der Voort ER, van der Ley P, van der Biezen J, et al. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun 1996, 64:2745-2751.
15. Russell JE, Jolley KA, Feavers IM, Maiden MC, Suker J PorA variable regions of Neisseria meningitidis. Emerg Infect Dis 2004, 10:674-678.
16. Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000, 182:1169-1176.
17. Anderson AS, Jansen KU, Eiden J New frontiers in meningococcal vaccines. Expert Rev Vaccines 2011, 10:617-634.
18. Van Der Ley P, Poolman JT Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun 1992, 60:3156-3161.
19. van der Ley P, van der Biezen J, Poolman JT Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 1995, 13:401-407.
20. Humphries HE, Williams JN, Blackstone R, et al. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 2006, 24:36-44.
21. Peeters CC, Rümke HC, Sundermann LC, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996, 14:1009-1015.
22. Kaaijk P, van Straaten I, van de Waterbeemd B, et al. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 2013, 31:1065-1071.
23. European Medicines Agency recommends approval of first vaccine for meningitis B, 2012 European Medicines Agency, (accessed Jan 31, 2014). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2012/11/WC500134846.pdf.
24. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011, 7:646-653.
25. Gossger N, Snape MD, Yu L-M, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582. the European MenB Vaccine Study Group.
26. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012, 379:617-624. for the V72P10 Meningococcal B Adolescent Vaccine Study group.
27. Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
28. Schneider MC, Prosser BE, Caesar JJE, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009, 458:890-893.
29. Seib KL, Serruto D, Oriente F, et al. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 2009, 77:292-299.
30. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003, 197:789-799.
31. Beernink PT, Shaughnessy J, Braga EM, et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 2011, 186:3606-3614.
32. Pajon R, Beernink PT, Harrison LH, Granoff DM Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010, 28:2122-2129.
33. Seib KL, Brunelli B, Brogioni B, et al. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 2011, 79:970-981.
34. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009, 27:2794-2803.
35. Marsh JW, Shutt KA, Pajon R, et al. Diversity of factor H-binding protein in Neisseria meningitidis carriage isolates. Vaccine 2011, 29:6049-6058.
36. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 2011, 18:1002-1014.
37. Brehony C, Wilson DJ, Maiden MCJ Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 2009, 155:4155-4169.
38. Capecchi B, Adu-Bobie J, Di Marcello F, et al. Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005, 55:687-698.
39. Comanducci M, Bambini S, Brunelli B, et al. NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002, 195:1445-1454.
40. Lucidarme J, Comanducci M, Findlow J, et al. Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010, 17:919-929.
41. Comanducci M, Bambini S, Caugant DA, et al. NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004, 72:4217-4223.
42. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010, 107:19490-19495.
43. Bai X, Borrow R Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines 2010, 9:1203-1217.
44. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007, 195:1472-1479.
45. Metruccio MME, Pigozzi E, Roncarati D, et al. A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 2009, 5:e1000710.
46. Fagnocchi L, Pigozzi E, Scarlato V, Delany I In the NadR regulon, adhesins and diverse meningococcal functions are regulated in response to signals in human saliva. J Bacteriol 2012, 194:460-474.
47. Fagnocchi L, Biolchi A, Ferlicca F, et al. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine. Infect Immun 2013, 81:560-569.
48. Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010, 107:3770-3775.
49. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006, 103:10834-10839.
50. Vu DM, Wong TT, Granoff DM Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 2011, 29:1968-1973.
51. Lucidarme J, Gilchrist S, Newbold LS, et al. Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica. Clin Vaccine Immunol 2013, 20:1360-1369.
52. Kuehn MJ, Kesty NC Bacterial outer membrane vesicles and thehost-pathogen interaction. Genes Dev 2005, 19:2645-2655.
53. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999, 162:3749-3752.
54. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
55. Fredriksen JH, Rosenqvist E, Wedege E, et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991, 14:67-79.
56. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835. for the EU Meningococcal B Infant Vaccine Study group.
57. Richmond P, Goldblatt D, Fusco PC, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 1999, 18:641-646.
58. Arnold R, Galloway Y, McNicholas A, O'Hallahan J Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011, 29:7100-7106.
59. Jackson C, Lennon D, Wong S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child 2011, 96:744-751.
60. Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001, 8:616-623.
61. Zollinger WD, Mandrell RE Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983, 40:257-264.
62. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28:6086-6093.
63. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010, 29:e71-e79.
64. Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 2013, 185:E715-E724.
65. Snape MD, Philip J, John TM, et al. Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial. Pediatr Infect Dis J 2013, 32:1116-1121.
66. Plikaytis BD, Stella M, Boccadifuoco G, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol 2012, 19:1609-1617.
67. Vogel U, Taha MK, Vazquez JA, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 2013, 13:416-425.
68. Hong E, Giuliani MM, Deghmane AE, et al. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?. Vaccine 2013, 31:1113-1116.
69. Kelly C, Arnold R, Galloway Y, O'Hallahan J A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007, 166:817-823.
70. Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013, 31:4968-4974.
71. Miller E, Salisbury D, Ramsay M Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(suppl 1):S58-S67.
72. JCVI interim position statement on the use of Bexsero meningococcal B vaccine in the UK Joint Committee on Vaccination and Immunisation, (accessed Jan 31, 2014). https://www.gov.uk/government/publications/jcvi-interim-position-statement-on-the-use-of-bexsero-meningococcal-b-vaccine-in-the-uk.
73. Update on the outcome of consultation about use of Bexsero® meningococcal B vaccine in the UK Joint Committee on Vaccination and Immunisation, (accessed Jan 31, 2014). https://www.gov.uk/government/publications/jcvi-update-on-the-use-of-bexsero-meningococcal-b-vaccine.
74. Minute of the meeting on Wednesday 2 October 2013 Joint Committee on Vaccination and Immunisation, (accessed Jan 31, 2014). http://www.gov.uk/government/policy-advisory-groups/joint-committee-on-vaccination-and-immunisation.
75. Measuring effectiveness and cost effectiveness: the QALY National Institute for Health and Care Excellence, (accessed April 19, 2013). http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp.
76. Christensen H, Hickman M, Edmunds WJ, Trotter CL Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013, 31:2638-2646.
77. Campbell H, Andrews N, Borrow R, Trotter C, Miller E Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010, 17:840-847.
78. Maiden MCJ, Stuart JM Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359:1829-1831. for the UK Meningococcal Carraige Group.
79. Maiden MCJ, Ibarz-Pavón AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008, 197:737-743.
80. Read RC, Baxter D, Chadwick DR, et al. Impact of a quadrivalent conjugate (MENACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan, Italy; May 28, 2013, to June 1, 2013 (accessed Jan 31, 2014). http://www2.kenes.com/ESPID2013/scientific/Documents/ESPID%20Final%20Scientific%20Programme.pdf.
81. Snape MD, Medini D, Halperin SA, DeTora L, Drori J, Moxon ER The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine 2012, 30(suppl 2):B67-B72.